Why AstraZeneca’s Olaparib Setback Could Be A Bigger Deal Than It Is
This article was originally published in The Pink Sheet Daily
Investors don’t have enormous expectations for olaparib in the small subset of ovarian cancer patients AstraZeneca was targeting for accelerated approval, but the negative FDA advisory committee review comes at a pivotal time for the company.
You may also be interested in...
With Day 2 of the BIO convention in San Diego in full swing, major deals, academic partnerships and hot pipelines take center stage – as long as they can be discussed in the World Cup Lounge.
Pfizer's biosimilar franchise is well on its way to becoming a blockbuster business three years after the company launched its first US biosimilar.
The partners have filed the first-in-class NGF inhibitor at the lower 2.5mg dose for the treatment of osteoarthritis pain, despite the drug’s challenging safety profile.